Ananya's Hidradenitis Suppurativa Journey
A 33-year-old woman with EPOH-DSS Stage 4 HS — nine years, three surgeries, biologics every three weeks — describes what changed when treatment moved from the skin to the drivers.
Read this storyAarav's Hidradenitis Suppurativa Journey
A 36-year-old IT professional with EPOH-DSS Stage 3 HS, flaring every three to four weeks despite continuous antibiotics, on what changed when treatment stopped chasing the lesions.
Read this storyNeha's Hidradenitis Suppurativa Journey
Inframammary HS is frequently mistaken for irritation or a hygiene problem. A 38-year-old woman on four years of recurrent under-breast lesions, and what actually changed them.
Read this storyAnika's Hidradenitis Suppurativa Journey
A 25-year-old woman with three years of HS in the underarms and groin, flaring with stress and menstruation — and what changed when the hormonal driver was finally treated as a driver.
Read this storyTwenty-One and Losing Weight Every Week
Ileocolonic Crohn's, three years, four to five watery stools a day and a body losing weight faster than he could eat it back. What moved, and what didn't.
Read this storyBullous Pemphigoid: a Taper-and-Flare Cycle
One case record: a woman of sixty-eight with biopsy-confirmed bullous pemphigoid, trapped in a taper-and-flare cycle on high-dose steroids. What the notes say, and do not.
Read this storyBullous Pemphigoid at 78, a Year of Fluctuation
One case record: bullous pemphigoid at seventy-eight, a year of fluctuation and escalating steroids. What the notes actually state, and where they are silent.
Read this storyNine hidradenitis suppurativa cases, photographed visit by visit
For hidradenitis suppurativa we publish a separate set of individually documented cases — each with its affected site, Hurley stage, disease duration and the photographic record at every documented visit, including the two that improved substantially without reaching full remission.
What these are, and are not. Individually documented courses of treatment with dated follow-up — not a controlled clinical trial, and not a claim about what any other patient should expect. Identifying details are withheld. Individual response varies with disease duration, extent of involvement and how much structural change has already occurred.
